**Pharmacy Pre-Authorization Criteria**

| **Drug(s)** | Amrix (cyclobenzaprine extended release capsules)  
Fexmid (cyclobenzaprine tablets) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Policy #</strong></td>
<td>14113</td>
</tr>
</tbody>
</table>
| **Indications** | Amrix is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.  
Fexmid is indicated as an adjunct to rest and physical therapy for short-term (2 to 3 weeks) relief of muscle spasm associated with acute, painful musculoskeletal conditions. |
| **Criteria** | ConnectiCare considers Amrix and Fexmid to be medically necessary for patients who meet the following criteria:  
1. Patient has a documented adequate trial of, or has shown an intolerance to, cyclobenzaprine immediate release tablets (Flexeril®) and at least two other muscle relaxant (tizanidine, baclofen, orphenadrine, carisoprodol, methocarbamol, chlorzoxazone, diazepam, or metaxalone (Skelaxin®)) |
| **Limitations** | • If the above criteria are met, approval may be granted for up to 1 month, due to lack of evidence of effectiveness for more prolonged use. Use of Amrix or Fexmid for periods longer than two or three weeks is not recommended by the manufacturer.  
• Based on the maximum daily dose the following quantities will be limited to 1 capsule per day. |
2. Facts and Comparisons online |
| **P&T Review History** | 3/08, 6/08, 9/08, 9/09, 9/10, 12/11, 10/12, 10/13, 10/14, 11/15, 11/16, 11/17 |
| **Revision Record** | 9/08, 11/16 |